We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$225M
AUM Growth
+$102M
Cap. Flow
+$112M
Cap. Flow %
49.73%
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$75M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$47.8M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
1
DELISTED
Akero Therapeutics
AKRO
$75.7M 33.61%
+3,954,858
New +$75M
DTIL icon
2
Precision BioSciences
DTIL
$189M
$56.5M 25.08%
142,171
– –
TPTX
3
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$54.5M 24.21%
+1,340,265
New +$47.8M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$25.3M 11.24%
1,000,000
-526,122
-34% -$10.7M
VYNE icon
5
VYNE Therapeutics
VYNE
$17M
$8.76M 3.89%
20,299
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$4.46M 1.98%
875,000
– –

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q2 2019 Portfolio in Review

As of Q2 2019, venBio Partners held 6 positions worth $225M, up 83% from $123M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $112M of net new capital in Q2 2019, opening 2 new positions. Its largest new stake was Akero Therapeutics: 3,954,858 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Apellis Pharmaceuticals, an estimated $10.7M trimmed.

  • venBio Partners's largest Q2 2019 buy was Akero Therapeutics: 3,954,858 shares worth $75.7M.
  • venBio Partners's biggest Q2 2019 reduction was Apellis Pharmaceuticals, cutting an estimated $10.7M.
  • venBio Partners's ten largest holdings make up 100% of its $225M portfolio in Q2 2019.
  • venBio Partners opened 2 new positions and closed 0 in Q2 2019.
  • venBio Partners's portfolio value rose 83% quarter-over-quarter to $225M.

Based on venBio Partners's 13F filing for Q2 2019, filed 14 Aug 2019.